Literature DB >> 24352646

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.

Blanca Espinet1, Ana Ferrer, Beatriz Bellosillo, Lara Nonell, Antonio Salar, Concepción Fernández-Rodríguez, Eulàlia Puigdecanet, Javier Gimeno, Mar Garcia-Garcia, Maria Carmen Vela, Elisa Luño, Rosa Collado, José Tomás Navarro, Esmeralda de la Banda, Pau Abrisqueta, Leonor Arenillas, Cristina Serrano, Josep Lloreta, Belén Miñana, Andrea Cerutti, Lourdes Florensa, Alberto Orfao, Ferran Sanz, Francesc Solé, David Dominguez-Sola, Sergio Serrano.   

Abstract

PURPOSE: According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1-positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases. EXPERIMENTAL
DESIGN: We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. Classification and regression trees strategy was used to generate an algorithm based on CD38 and CD200 expression by flow cytometry.
RESULTS: We found 171 differentially expressed genes with enrichment of neoplastic behavior and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to immune activation and inflammatory responses. CD38 and CD200 were differentially expressed between MCL and MALD1 and confirmed by flow cytometry (median CD38, 89% vs. 14%; median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% (11 of 13) of MALD1 cases whereas 15% remained unclassified. SOX11 expression by qRT-PCR was significantly different between MCL and MALD1 groups but did not improve the classification.
CONCLUSION: We show for the first time that MALD1, in contrast to MCL, is characterized by immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. MALD1 should be identified and segregated from the current MCL category to avoid overdiagnosis and unnecessary treatment. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352646      PMCID: PMC4488901          DOI: 10.1158/1078-0432.CCR-13-1077

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

Authors:  Lina Nygren; Stefanie Baumgartner Wennerholm; Monika Klimkowska; Birger Christensson; Eva Kimby; Birgitta Sander
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

2.  Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study.

Authors:  Antonio Salar; Nuria Juanpere; Beatriz Bellosillo; Eva Domingo-Domenech; Blanca Espinet; Agustín Seoane; Vicente Romagosa; Eva Gonzalez-Barca; Agustín Panades; Carmen Pedro; Miguel Nieto; Eugenia Abella; Francesc Solé; Aurelio Ariza; Alberto Fernández-Sevilla; Carlos Besses; Sergio Serrano
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

Review 3.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.

Authors:  Maria Carmela Vegliante; Jara Palomero; Patricia Pérez-Galán; Gaël Roué; Giancarlo Castellano; Alba Navarro; Guillem Clot; Alexandra Moros; Helena Suárez-Cisneros; Sílvia Beà; Luis Hernández; Anna Enjuanes; Pedro Jares; Neus Villamor; Dolors Colomer; José Ignacio Martín-Subero; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

8.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

9.  Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.

Authors:  Laurentia Nodit; David W Bahler; Samuel A Jacobs; Joseph Locker; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2003-10       Impact factor: 3.466

10.  Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion.

Authors:  Menno C van Zelm; Tomasz Szczepanski; Mirjam van der Burg; Jacques J M van Dongen
Journal:  J Exp Med       Date:  2007-02-20       Impact factor: 14.307

View more
  16 in total

1.  SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.

Authors:  J Palomero; M C Vegliante; A Eguileor; M L Rodríguez; P Balsas; D Martínez; E Campo; V Amador
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 2.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 3.  Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.

Authors:  Sílvia Beà; Virginia Amador
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

Review 4.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

5.  Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.

Authors:  Inmaculada Ribera-Cortada; Daniel Martinez; Virginia Amador; Cristina Royo; Alba Navarro; Silvia Beà; Eva Gine; Laurence de Leval; Sergio Serrano; Andrew Wotherspoon; Dolors Colomer; Antonio Martinez; Elías Campo
Journal:  Mod Pathol       Date:  2015-09-11       Impact factor: 7.842

6.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Authors:  Zhihong Hu; Yi Sun; Ellen J Schlette; Guilin Tang; Shaoying Li; Jie Xu; C Cameron Yin; Ken H Young; Keyur Pravinchandra Patel; Roberto N Miranda; Maitrayee Goswami; Michael Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Sa A Wang
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

7.  Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation.

Authors:  Mariko Yabe; Neval Ozkaya; Daphne de Jong; Umut Aypar; M Stella Ritorto; Ellis Barbé; Iris H C Miedema; Filiz Sen; Jessica R Chapman; Heather J Landau; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2021-07-01       Impact factor: 6.298

Review 8.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

Review 9.  Progress in molecular feature of smoldering mantle cell lymphoma.

Authors:  Panruo Jiang; Aakash Desai; Haige Ye
Journal:  Exp Hematol Oncol       Date:  2021-07-13

10.  A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Authors:  Guillem Clot; Pedro Jares; Eva Giné; Alba Navarro; Cristina Royo; Magda Pinyol; David Martín-Garcia; Santiago Demajo; Blanca Espinet; Antonio Salar; Ana Ferrer; Ana Muntañola; Marta Aymerich; Hilka Rauert-Wunderlich; Elaine S Jaffe; Joseph M Connors; Randy D Gascoyne; Jan Delabie; Armando López-Guillermo; German Ott; George W Wright; Louis M Staudt; Andreas Rosenwald; David W Scott; Lisa M Rimsza; Sílvia Beà; Elías Campo
Journal:  Blood       Date:  2018-05-16       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.